Erbitux and Macugen priced and set for Japanese launch
This article was originally published in Scrip
Executive Summary
The next reimbursement price listing of pharmaceuticals in Japan will include two important new therapies, Erbitux (cetuximab) for colorectal cancer and Macugen (pegaptanib) for age-related macular degeneration.